Guggenheim analyst Yatin Suneja downgraded Vigil Neuroscience (VIGL) to Neutral from Buy with an $8 price target after the company agreed to be acquired by Sanofi (SNY).
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience downgraded to Market Perform from Outperform at William Blair
- Vigil Neuroscience downgraded to Market Perform from Outperform at Citizens JMP
- Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
- Vigil Neuroscience Inc trading halted, news pending
- Vigil Neuroscience Advances Clinical Trials and Financial Stability